Taizo Matsuki, n/a

MSD K.K., Japan

Disclosure(s): GSK: Past employee by October 2023; MSD: Stocks/Bonds (Public Company), Study and publication fund

Poster(s):

• (P-658) Cost-Effectiveness of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, vs. PCV20 on Pneumococcal Disease in Japan--A Delta-Price Approach
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT